- Supreme Court overturns Roe v. Wade 6-3, ending constitutional protections for abortion
- Beta-vax: Sanofi, GSK hail phase 3 omicron win to throw down gauntlet in COVID-19 vaccine format war
- CVS re-adds BMS, Pfizer's Eliquis to formulary after tough negotiations, patient pushback
- Novo Nordisk, Echosens aim to double NASH diagnostic rate by expanding test options, awareness
- M&A is down, but Big Pharma likely to line up 'multiple shots on goal' in 2nd half, PwC says
- BioMarin's hemophilia gene therapy Roctavian wins conditional EU backing amid FDA delay
- CMS approves first-ever public option plan for Colorado's ACA exchange
- Lilly and Boehringer's Jardiance poised for challenge to AZ's market leader Farxiga in chronic kidney disease: Spherix
- Elucid clears $27M funding for heart disease diagnostic AI
- Acquisition in the air? Merck and Seagen to meet this week: WSJ
- Galapagos says out with the old, in with the new, as respiratory drug sent back to Molecure
- Digital health startup Ro cuts 18% of workforce citing current economic climate
- Sarepta defuses concerns about Duchenne clinical hold with vow to meet FDA's request within days
- Roche continues to salute the diversity of the MS community with latest work
- Fujifilm picks up AI program for guiding IVF procedures
Featured Story | By Dave Muoio "With Roe gone, let’s be very clear: The health and life of women in this nation are now at risk.” President Joe Biden said in remarks following the release of the Supreme Court's decision. read more |
| |
|---|
|
|  | L.E.K.’s Looking Ahead 2022 series of Executive Insights looks at how accelerated innovation has brought both unprecedented achievement and enduring challenges for companies throughout the healthcare ecosystem. Click to read more. |
|---|
Top Stories By Nick Paul Taylor After lagging the leaders in the original COVID-19 vaccine race, Sanofi and GSK have now claimed a first in the push to protect people from omicron. The partners hailed the first successful efficacy study against omicron after their beta-specific vaccine achieved 72% protection versus the now-dominant variant. read more By Zoey Becker After a wave of criticism and tough pricing negotiations, CVS Health has changed course and is returning BMS and Pfizer's Eliquis to its preferred formulary on July 1. read more By Andrea Park Through their partnership, Echosens and Novo Nordisk will work together to bulk up the clinical and real-world evidence to back up Echosens’ FibroScan system as a valid option for NASH diagnosis and monitoring. In doing so, they’re aiming to vastly increase worldwide adoption of noninvasive screening methods for the disease from Echosens and other developers. read more By Annalee Armstrong Deal values are down by 58% and volume has decreased by 33%, but fear not, the pharmaceutical and life sciences industry is poised for a “flurry of deals” in the second half, according to PwC. read more By Angus Liu The future of BioMarin’s first-of-its-kind hemophilia gene therapy remains uncertain at the FDA, but its EU regulatory path now looks clearer. Despite questions about the one-time drug's long-term efficacy, the EMA has recommended a conditional nod. read more By Robert King HHS approved a waiver for Colorado to create its own public option plan to be sold on the Affordable Care Act's exchanges. read more By Natalie Missakian Eli Lilly and Boehringer Ingelheim made news last spring with the early halt of a trial testing its SGLT2 inhibitor Jardiance for chronic kidney disease thanks to “clear positive efficacy,” and HCPs are taking notice, setting it up for a potential challenge to AstraZeneca’s market leader Farxiga, a new analysis suggests. read more By Andrea Park No, it’s not a dream—Boston-based startup Elucid has closed its largest fundraising session yet, a funding round that more than triples the $8 million series A it unveiled around this time last year. read more By Kevin Dunleavy In the ongoing saga of whether Merck will acquire formidable biotech Seagen, the companies have scheduled a meeting this week, sources told The Wall Street Journal on Thursday. Others are eyeing the Seattle firm, people have told the WSJ, but none of those companies have been identified. read more By Annalee Armstrong While Galapagos is stocking its pipeline by way of two acquisitions, the biotech is also cleaning house, sending the rights for a respiratory disease drug back to Molecure. read more By Heather Landi Digital health startup Ro, which hit a $7 billion valuation back in February, is laying off 18% of its workforce amid a market downturn. read more By Nick Paul Taylor Sarepta Therapeutics has successfully defused concerns about a FDA clinical hold on one of its Duchenne muscular dystrophy clinical trials. After initially plunging, the biotech’s share price stabilized when it reassured investors it could satisfy the regulator’s requests “in the next few days” and convinced analysts of the likelihood of a speedy resolution. read more By Sharon Klahr Coey “Community” is tossed around as a buzzword for many drugs and many disease states, but the patients on Roche Genentech’s Ocrevus have taken their community so far as to have their own hand signal. read more By Conor Hale Fujifilm has licensed a program developed by researchers at Brigham and Women’s Hospital and Massachusetts General Hospital designed to boost the procedure’s success. read more |
|
